Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in achieving adequate control of motor complications in patients with advanced Parkinson’s Disease (APD). Background:…The effect of levodopa on the blood activity of calpains in patients with Parkinson’s disease
Objective: To evaluate the effect of levodopa on the blood activity of calpains in patients with PD Background: Parkinson's disease (PD) is a chronic progressive…Machine Learning Model for Prediction of acute orthostatic hypotension after levodopa administration
Objective: The aim of this study is to develop and validate a prediction model of AOHPL to facilitate physicians in identifying patients at higher probability…Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson’s disease
Objective: To identify factors predictive of responsiveness of tremor to levodopa and STN-DBS. Background: Tremor in Parkinson’s disease (PD) is phenotypically variable and has an…Levodopa-induced orthostatic hypotension in a large cohort of patients with Parkinson’s disease undergoing an acute levodopa challenge test
Objective: We aimed to investigate the frequency and associated risk factors for Levodopa-induced orthostatic hypotension (OH) in a large cohort of PD patients underwent acute…15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation
Objective: PD MED EARLY is a large, pragmatic trial aiming to determine which class of drug as initial treatment provides the most effective long-term control…Reductions in OFF time with ND0612 for patients with Parkinson’s disease experiencing motor fluctuations: Responder-analysis from an open-label Phase 2 study
Objective: Evaluate the efficacy of subcutaneous levodopa/carbidopa infusion with investigational ND0612 in reducing OFF time in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background:…Developement and acceptability testing of a patient decision aid on levodopa/carbidopa intestinal gel.
Objective: To develop a patient decision aid on levodopa/carbidopa intestinal gel (LCIG) and to test its acceptability. Background: : Advanced Parkinson’s disease (PD) is characterized…How to dose extended-release carbidopa-levodopa capsules (IPX203) in Parkinson’s disease patients: Experience from the Phase 3 clinical trial
Objective: To provide guidance on dosing of IPX203 based on clinical trial experience. Background: IPX203 is an extended-release, oral carbidopa-levodopa (CD-LD) formulation designed to rapidly…Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease
Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 62
- Next Page »